Paragon 28, Inc. (FNA)
(Delayed Data from NYSE)
$6.64 USD
-1.67 (-20.10%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $6.80 +0.16 (2.41%) 6:40 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
FNA 6.64 -1.67(-20.10%)
Will FNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FNA
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
FNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Top Estimates
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
Other News for FNA
Paragon 28 falls -22.9%
Buy Rating for Paragon 28: Strong Growth and Strategic Initiatives Signal Market Share Expansion in Orthopedics
Paragon 28 price target lowered by $3 at Piper Sandler, here's why
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Buy Rating Affirmed for Paragon 28 Amid Revenue Growth and Positive EBITDA Outlook